University Hospitals of North Midlands NHS Trust

UHNM Becomes First UK Site to Recruit Patient for BioNTech's Phase 3 Small-Cell Lung Cancer Trial

- University Hospitals of North Midlands NHS Trust has become the first NHS Trust in the UK to recruit a patient onto BioNTech's international phase 3 trial for small-cell lung cancer. - The trial investigates BNT327, a novel drug combining immunotherapy and anti-angiogenic properties, in combination with standard chemotherapy for this rare but aggressive cancer. - This represents the first new treatment research for small-cell lung cancer patients in twenty years, addressing a significant unmet medical need in oncology. - The randomized controlled trial will evaluate efficacy, safety, pharmacokinetics, and quality of life outcomes compared to existing standard treatments.